incubated in alkaline peptone water (pH 8.6) for 6-8 h at 37°C and then plated onto the agar. After overnight incubation at 37°C, suspected colonies were tested biochemically and confi rmed by slide agglutination with polyvalent O1 and monovalent Ogawa and Inaba antiserum (Difco Laboratories, Detroit, MI, USA).
Antimicrobial drug susceptibility testing was performed by using the disk diffusion technique on MuellerHinton agar (Difco Laboratories) with commercial disks (Oxoid, Cambridge, UK) and appropriate control strains (2) Figure, www.cdc.gov/ EID/content/17/3/568-appF.htm).
Among the tetracycline-resistant isolates (101 randomly selected strains), 43% had high-level resistance (MIC >16 μg/mL). In addition, 57% of V. cholerae O1 organisms had reduced susceptibility (i.e., MICs ranged from 8 μg/mL to 16 μg/mL).
Tetracycline is the drug of choice for treating cholera (1); however, during the 6-year period, we observed the emergence of tetracycline resistance among V. cholerae O1 isolates and a sudden upsurge in such resistance in 2007 when 76% of the isolates were resistant. Tetracycline resistance was also reported by Mhalu et al. (3) , from an epidemic of cholera in Tanzania, where 76% of isolates were found to be resistant after 5 months of extensive use of this drug for treatment and prophylaxis. In a similar situation, the extensive prophylactic use of tetracycline triggered the rapid emergence and spread of tetracyclineresistant strains in Madagascar (4). Tetracycline is not used for prophylaxis in Kolkata, a known cholera-endemic area. Nonetheless, the emergence of resistant strains in our study area is not surprising because similar tetracycline-resistant strains of V. cholerae have been reported in Bangladesh (5), in Mozambique (6), and in another study of Kolkata (7) . Notably, tetracycline-resistant V. cholerae O1 strains have also been responsible for major epidemics in Latin America, Tanzania, Bangladesh, and Zaire (8) .
In our study, resistance to tetracycline among V. cholerae O1 isolates was <10% during [2004] [2005] [2006] . The reasons for the sudden rise of resistant strains in 2007 and their continued persistence are still unclear. Detailed molecular studies are underway to fi nd the explanation. Alternative drugs, such as the newer fl uoroquinolones, possess excellent activity against V. cholerae O1 and O139 serogroups. However, increased resistance to newer fl uoroquinolones, such as ciprofl oxacin and norfl oxacin, among V. cholerae strains belonging to O1 serogroup has also been reported (9) .
Resistance to commonly used antimicrobial drugs represents a critical public health problem because it complicates treatment and may result in longer hospital stays for patients. In addition, most of the population in developing countries cannot afford the newer and more expensive drugs. Our fi ndings emphasize the need for continued surveillance of antimicrobial drug susceptibility patterns of V. cholerae. Providing early information on antimicrobial drug susceptibility to practitioners in affected areas will lessen the illness and death from this devastating disease. 
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Neisseria meningitidis Strain of Unknown Serogroup, China
To the Editor: Neisseria meningitidis is a major public health hazard in many parts of the world. This organism is classifi ed into 13 serogroups, and most meningococcal disease is caused by strains that express 1 of the 5 types of capsular polysaccharides (A, B, C, Y, and W135). In the natural reservoir of the human nasopharynx, strains of N. meningitidis that do not fi t into 1 of the 13 serogroups and are presumably unencapsulated are common. By contrast, rare meningococcal diseases are caused by these nonserogroupable strains. In this article, we describe a case of N. meningitidis infection caused by a nonserogroupable strain in the People's Republic of China and the genotype characteristics of this strain.
The patient was a 6-month-old boy who was admitted to a local hospital in Beijing in May 2009. The infection started suddenly with high fever (39°C). N. meningitidis infection was confi rmed on the basis of the clinical signs and results of laboratory examination. Nausea, vomiting, and neck stiffness developed, and the patient lost consciousness. Physical examination showed a positive Kernig sign and negative Brudzinski sign. The patient's cerebrospinal fl uid sample was injected into chocolate agar, in which microbial growth was observed after 24 hours. The API NH system (bioMérieux, Marcy-Etoile, France) showed that the isolate was N. meningitidis. However, this strain could not be placed in a serogroup, even after specifi c antiserum (Remel, Lenexa, KS, USA) was used. No other disease with complement defi ciency was detected in the patient. The patient's infection was treated with antimicrobial drugs, and he recovered completely.
We investigated this nonserogroupable N. meningitidis strain by multilocus sequence typing (MLST), pulsed-fi eld gel electrophoresis (PFGE), and subtyping of the variable regions of the genes (porA, porB, and fetA) encoding the outer membrane proteins. MLST indicated that the fumC was a new allele with a new number 482. The allele numbers for abcZ, adk, fumC, gdh, pdhC, and pgm were 222, 3, 58, 386, 18, and 77, respectively. This strain was assigned a new sequence type number, ST7962.
Among the 44 complexes designed in the MLST database, ST7962 was most similar to the ST4821 complex with 3 identical loci. The PFGE pattern of this strain was compared with the PFGE
